Decreased coverage of HAS2 immunostaining in melanoma cells was associated with several histopathological factors, including reduced number of tumor infiltrating lymphocytes (TILs) (p = 0.036) and increased horizontal tumor diameter (p = 0.002; Table 2). This evidence concerns the gene HAS2 and melanoma.